期刊文献+

卵巢癌抗血管靶向治疗临床研究进展 被引量:7

The Progress in Anti-Vascular Target Therapy in Ovarian Cancer
下载PDF
导出
摘要 靶向治疗是针对肿瘤组织有别于正常组织的特征,给予有针对性的治疗,从而达到较好治疗效果和较小的不良反应。目前抗肿瘤靶向治疗研究中最多的是抗血管治疗,不断研发出许多新的药物,并已广泛用于临床试验。对近年来卵巢癌抗血管靶向治疗的临床研究加以综述,以介绍这一新治疗方法在卵巢癌中的治疗现状、面临问题和前景。 Target therapy focus on the tumor's characteristics which are different from normal tissues. So as to gain higher therapeutic effect with lower adverse effect. At present, most of the research of target therapy is about anti-vascular therapy.Intense researches and development activities have resulted in a variety of investigational agents, a number of which are currently he used in clinical experiments. This paper reviewed the clinical trials of anti- vascular target therapy in ovarian cancer, in order to know about the current situation and the prospective research of the treatment in ovarian cancer.
出处 《国际妇产科学杂志》 CAS 2010年第4期271-273,293,共4页 Journal of International Obstetrics and Gynecology
关键词 卵巢肿瘤 血管内皮生长因子类 治疗 临床试验 Ovarian neoplasms Vascular endothelial growth factors Therapy Clinical trial
  • 相关文献

参考文献21

  • 1Monk BJ,Han E,Josephs-Cowan CA,et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxie regimens in advanced refractory epithelial ovarian cancer [J]. Gynecol Onco1,2006,102(2) : 140-144.
  • 2Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent,platinum-refractory,epithelial ovarian carcinoma : A retrospective analysis [J ]. Cancer, 2006,107 ( 1 ) : 83-89.
  • 3Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression- free survival with weekly paelitaxel and bevacizumab in recurrent ovarian cancer [ J ]. Gynecol Oncol,2009,115 (3) : 396-400.
  • 4Garcia AA,Hirte H,Fleming G,et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California,Chicago,and Princess Margaret Hospital phase II consortia [J ]. J Clin Oncol, 2008,26( 1 ) :76-82.
  • 5Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [J]. J Clin Oncol, 2007,25 (33) :5180-5186.
  • 6Burger RA,Sil! MW,Monk BJ,et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer:a Gynecologic Oncology Group study [J ]. J Clin Oncol ,2007,25 (33) :5165-5171.
  • 7Tao X,Sood AK,Deavers MT,et al.Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors [J]. Gynecol Oncol, 2009,114 (3) : 43 1-436.
  • 8Gordon AN,Finkler N,Edwards RP,et al. Efficacy and safety of erlotinib HCI ,an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor,in patients with advanced ovarian carcinoma: results from a phase II muhicenter study[J]. Int J Gynecol Cancer, 2005,15(5) :785-792.
  • 9Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression :a Gynecologic Oncology Group Study [ J ]. Clin Cancer Res, 2005,11 ( 15 ) : 5539-5548.
  • 10Schilder R J, Sill MW, Lee RB, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma:a Gynecologic Oncology Group Study [ J ]. J Clin Oncol, 2008,26 (20) : 3418-3425.

同被引文献62

  • 1孙斌,瞿伟菁,张晓玲,杨煌建,庄秀园,章平.蒺藜皂苷对人肝癌细胞BEL7402生长抑制和诱导凋亡作用的研究[J].中国中药杂志,2004,29(7):681-684. 被引量:17
  • 2李山,秦雪,何卫华.血清CA125在卵巢癌诊断中的价值及文献评价[J].中华检验医学杂志,2005,28(2):209-211. 被引量:37
  • 3杨煌建,瞿伟菁,孙斌.蒺藜皂苷对肾癌细胞的实验影响[J].中国中药杂志,2005,30(16):1271-1274. 被引量:9
  • 42012 NCCN卵巢癌临床实践指南(第二版)[S].2012.
  • 5Pegasus Pharmaceuticals Group Inc.[EB/OL].(2014-10-23).[2014-11-01].http://www.panagin.com/.
  • 6CHMP.Lynparza [EB/OL].(2014-10-23).[2014-11-01].http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003726/WC500176336.pdf.
  • 7ASCO.The combination of olaparib and cediranib significantly improves progression-free survival in recurrent ovarian cancer [EB/OL].(2014-06-01).[2014-11-01].http://am.asco.org/combination-olaparib-and-cediranib-significantly- improves-progression-free-survival-recurrent.
  • 8吴小华.吴小华谈复发卵巢癌联合靶向治疗试验 [EB/OL].(2014-05-28).[2014-11-01].http://cancer.cmt.com.cn/detail/514317.html.
  • 9许景红.cediranib可改善铂敏感复发性卵巢癌的生存[EB/OL].(2013-10-17).[2014-11-01].http://cancer.cmt.com.cn/detail/341613.html.
  • 10ASCO.A randomised placebo-controlled phase II study of continuous maintenance treatment with BIBF 1120 following chemotherapy in patients with relapsed ovarian cancer [EB/OL].(2014-05-28).[2014-11-01].http://www.clinicaltrials.gov/ct2/show/record/NCT00710762.

引证文献7

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部